Lisa A. Kottschade

Mayo Clinic — United States

Medicine · Health Sciences

38h-index6.1kcitations236works1.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(103), Cutaneous Melanoma Detection and Management(83), CAR-T cell therapy research(75), Melanoma and MAPK Pathways(35), Immunotherapy and Immune Responses(31)

Publications236 total

Atrial Arrhythmia Incidence and Outcomes in Patients Treated with Immune Checkpoint Inhibitor Therapy
The American Journal of Cardiology·2026
Urinary CXCL-9 Outperforms TNF-α for Non-invasive Diagnosis of Immune Checkpoint Inhibitor-Associated Acute Interstitial Nephritis
Nephrology Dialysis Transplantation·2026· 1 cited
Supplementary Figure S1 from SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma
2025Open Access
Supplementary Table S2 from SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma
2025Open Access
Supplementary Table S5 from SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma
2025Open Access
Supplementary Table S4 from SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma
2025Open Access
Supplementary Table S3 from SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma
2025Open Access
Supplementary Table S1 from SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma
2025Open Access
Case Report: Complete pathologic response in advanced melanoma with SFRT and dual checkpoint inhibition
Frontiers in Oncology·2025Open Access
Outcomes in Patients With Immune Checkpoint Inhibitor–Related Myopathy and Prolonged Follow-Up
Neurology Neuroimmunology & Neuroinflammation·2025· 3 citedOpen Access
S5626 Interleukin-6 Is a Potential Therapeutic Target in Refractory Immunotherapy-Mediated Cholangiopathy
The American Journal of Gastroenterology·2025
1518MO Rescuing cancer immunotherapy with plasma exchange in melanoma (the ReCIPE-M1 study)
Annals of Oncology·2025
NeoACTIVATE Arm C: Phase II trial of neoadjuvant atezolizumab and tiragolumab for high-risk operable Stage III melanoma
European Journal of Cancer·2025Open Access
Supporting Administrative Time for Advanced Practitioners: A Comprehensive Approach
Journal of the Advanced Practitioner in Oncology·2025Open Access
NeoACTIVATE arm C: Phase II trial of neoadjuvant atezolizumab and tiragolumab for high-risk operable stage III melanoma.
Journal of Clinical Oncology·2025
Clinical characteristics, outcomes, and predictive modeling of patients diagnosed with immune checkpoint inhibitor therapy-related pneumonitis
Cancer Immunology Immunotherapy·2025· 5 citedOpen Access
Navigating skin toxicity in the era of immunotherapy
Journal of Dermatology for Physician Assistants·2025· 1 cited
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial
Journal for ImmunoTherapy of Cancer·2025· 6 citedOpen Access
Tumor-Infiltrating Lymphocyte Cell Therapy for the Treatment of Advanced Melanoma: From Patient Identification to Posttreatment Management
Journal of the Advanced Practitioner in Oncology·2025Open Access
Plasma exchange and radiation resensitize immunotherapy-refractory melanoma: a phase I trial
Nature Communications·2025· 5 citedOpen Access
page 1 of 12Next →

Frequent Co-authors

Svetomir N. Markovic(29), Robert R. McWilliams(12), Roxana Dronca(12), Matthew S. Block(7), Charles L. Loprinzi(6), Edward T. Creagan(6), Debra L. Barton(5), Lori A. Erickson(5), José S. Pulido(5), Mabel Ryder(5), Heidi D. Finnes(5), Jennifer L. Hand(4), Vera J. Suman(4), Tom R. Fitch(4), Judith S. Kaur(4), Jacob B. Allred(4), Ravi D. Rao(3), Roger H. Weenig(3), Mark R. Pittelkow(3), Barbara A. Pockaj(3)